New Investigators. We are requesting $150,000 per year to support 2-3 new investigators for one to three years for start-up of their research. The recruitments occur in partnership with Departments, and can be initiated by either partner. The funds are intended to guarantee technical support and supplies for junior-level investigators. However, it is possible that these funds could be combined into a larger package for a more senior individual. The University of Virginia will pay for the salary and most of the equipment costs of these recruits, and in addition the Cancer Center has available $500,000 per year from the School of Medicine to aid in recruitment. Further matching almost invariably is obtained from the Department that we partner with in these recruitments. Thus, funds from the CCSG permit the Cancer Center to leverage a relatively modest investment into a considerable influence on the future of the University of Virginia Health Sciences Center. As described in Section 6.3, our focus for recruitments during the next funding period will be to bolster clinical investigations, strengthen cancer-focused basic and translational research, and strengthen Cancer Control. Clinical investigators will be chosen who will work well within our collaborative environment, and who have an interest and expertise in molecularly targeted therapies, biomarkers, and imaging, especially in the major solid tumors. Translational investigators will be recruited to help development of translational working groups, especially in the areas of immunotherapy, women's oncology, prostate cancer, and aerodigestive cancers. In addition, we will look for opportunities to partner with basic science departments, to recruit outstanding cancer-focused basic scientists, with the Departments of Biomedical Engineering and Radiology to bolster our capability in cancer imaging, and with the Department of Public Health Sciences, to strengthen the foundation for movement toward Comprehensive status.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA044579-17
Application #
7726738
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-02-01
Budget End
2008-01-31
Support Year
17
Fiscal Year
2007
Total Cost
$51,524
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :
Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8
Kiran, Shashi; Dar, Ashraf; Singh, Samarendra K et al. (2018) The Deubiquitinase USP46 Is Essential for Proliferation and Tumor Growth of HPV-Transformed Cancers. Mol Cell 72:823-835.e5
Conaway, Mark R; Petroni, Gina R (2018) The Impact of Early-Phase Trial Design in the Drug Development Process. Clin Cancer Res :
Szlachta, Karol; Kuscu, Cem; Tufan, Turan et al. (2018) CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nat Commun 9:4275
Khalil, Shadi; Delehanty, Lorrie; Grado, Stephen et al. (2018) Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J Exp Med 215:661-679
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437

Showing the most recent 10 out of 539 publications